Cetuximab

About

Therapy type: Targeted therapy

Therapy strategy: EGFR inhibition

Mappings

NCI Thesaurus: Cetuximab (ncit:C1723)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan
FDA (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
FDA (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab
EMA (1) FDA (2) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib
FDA (1) KRAS p.G12C Colorectal Adenocarcinoma Adagrasib, Cetuximab
FDA (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Oxaliplatin
HSE (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan